Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: Cancer Gene Ther. 2011 Jan 14;18(5):326–335. doi: 10.1038/cgt.2010.82

Figure 2. HER2/neu transgene specific CMI after immunization with Ad5 [E1-, E2b-]-HER2.

Figure 2

Ad5 naïve (A) or Ad5 immune (B) BALB/c mice (n=5/group) were immunized one, two or three times at a seven day intervals with 1010 VP Ad5 [E1-, E2b-]-HER2/neu. Splenocytes were assessed 14 days following the final immunization for IFN-γ and IL-2 secretion by ELISpot assay. No significant CMI responses were observed when splenocytes were exposed to β-galactosidase protein, CMV peptides, or HIV-1 Gag protein (data not shown). Error bars indicate the standard error from the mean.